Anaphylaxis events following COVID-19 antiviral and neutralising monoclonal antibody treatment for non-hospitalised patients: data from the OpenSAFELY-TPP platform
Zheng B., Green ACA., Nab L., Tazare J., Bechman K., Mehrkar A., Hulme WJ., MacKenna B., Goldacre B., Douglas I., Tomlinson LA.
Background: Limited evidence is available regarding the anaphylaxis risk following the administration of COVID-19 therapeutics. Methods: With the approval of NHS England, we conducted a descriptive analysis of anaphylaxis events following COVID-19 treatment for non-hospitalised patients using routine clinical data from 24 million people in England in the OpenSAFELY-TPP database. Results: We found that the risk of anaphylaxis during the 29 days follow-up was 0.04% for sotrovimab users, 0.03% for Paxlovid users, <0.05% for molnupiravir users, and 0.02% for untreated high-risk patients. Conclusions: Our results suggest that anaphylaxis risks were similar between sotrovimab and Paxlovid users, which were not appreciably different from untreated patients.